Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.

Reis, Rafael

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. [electronic resource] - Journal of pharmaceutical and biomedical analysis Sep 2018 - 174-183 p. digital

Publication Type: Journal Article; Validation Study

1873-264X

10.1016/j.jpba.2018.05.052 doi


Acrylamides
Afatinib
Aniline Compounds
Antineoplastic Agents--blood
Carcinoma, Non-Small-Cell Lung--blood
Chromatography, High Pressure Liquid
Crizotinib
Drug Monitoring--methods
Drug Stability
ErbB Receptors--antagonists & inhibitors
Erlotinib Hydrochloride--blood
Humans
Indoles--blood
Limit of Detection
Lung Neoplasms--blood
Piperazines--blood
Protein Kinase Inhibitors--blood
Pyrazoles--blood
Pyridines--blood
Quinazolines--blood
Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors
Reproducibility of Results
Sensitivity and Specificity
Tandem Mass Spectrometry